The longest ever randomised controlled trial of insulin glargine: study design and HbA1c findings

被引：10

作者：

Currie, C. J. ^{[1
]}

机构：

[1] Cardiff Univ, Sch Med, Pharma Res Ctr, Cardiff MediCtr, Cardiff CF14 4UJ, S Glam, Wales

来源：

DIABETOLOGIA | 2009年 / 52卷 / 10期

关键词：

Metformin; Insulin Glargine; Proliferative Diabetic Retinopathy; Insulin Detemir; Insulin Regimen;

D O I：

10.1007/s00125-009-1477-6

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：2234 / 2235

页数：2

共 5 条

[1] The influence of glucose-lowering therapies on cancer risk in type 2 diabetes [J].

Currie, C. J. ;

Poole, C. D. ;

Gale, E. A. M. .

DIABETOLOGIA, 2009, 52 (09) :1766-1777

[2] The prescription cost of managing people with type 1 and type 2 diabetes following initiation of treatment with either insulin glargine or insulin detemir in routine general practice in the UK: a retrospective database analysis [J].

Poole, Chris D. ;

Tetlow, Tony ;

McEwan, Phil ;

Holmes, Paul ;

Currie, Craig J. .

CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 :S41-S48

[3] Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study [J].

Rosenstock, J. ;

Fonseca, V. ;

McGill, J. B. ;

Riddle, M. ;

Halle, J. P. ;

Hramiak, I. ;

Johnston, P. ;

Davis, M. .

DIABETOLOGIA, 2009, 52 (09) :1971-1973

[4] Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study [J].

Rosenstock, J. ;

Fonseca, V. ;

McGill, J. B. ;

Riddle, M. ;

Halle, J. -P. ;

Hramiak, I. ;

Johnston, P. ;

Davis, M. .

DIABETOLOGIA, 2009, 52 (09) :1778-1788

[5] Does diabetes therapy influence the risk of cancer? [J].

Smith, U. ;

Gale, E. A. M. .

DIABETOLOGIA, 2009, 52 (09) :1699-1708

← 1 →